Tokyo, Nov. 22 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063718) titled 'A retrospective observational study of the association between changes in measured MFU% (multi-hair follicular unit rate) and treatment response across different treatment strategies for male androgenetic alopecia' on Nov. 22.

Study Type: Observational

Primary Sponsor: Institute - Tokyo midtown Center for Advanced Medical Science and Technology

Condition: Condition - Male androgenetic alopecia Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To investigate the association between treatment response (responders vs. non-responders) at 12 months after initial treatment and the change in measured multi-hair follicular unit percentage from baseline to 12 months in patients with male androgenetic alopecia. Basic objectives2 - Safety,Efficacy

Eligibility: Age-lower limit - 20 years-old = Gender - Male Key inclusion criteria - Patients must meet all of the following criteria to be eligible for inclusion in this study: 1. Male patients diagnosed with male androgenetic alopecia. 2. Patients who can be classified into one of the five treatment groups defined in this study: SHED-CM monotherapy, needle radiofrequency (RF) monotherapy, alternating SHED-CM and needle RF therapy, same-day combined SHED-CM and needle RF therapy, or dutasteride monotherapy. 3. Availability of clinical information and trichoscopic images at baseline (T0), before treatment initiation. 4. Availability of trichoscopic images at approximately 12 months after treatment initiation (T12). 5. Availability of evaluable multi-hair follicular unit percentage (MFU%) and QTES measurements from images obtained at both T0 and T12. Key exclusion criteria - Patients meeting any of the following criteria will be excluded from the study: 1. Patients with alopecia other than male androgenetic alopecia (MAGA), or whose hair loss is considered primarily attributable to another disease. 2. Patients with concomitant alopecia areata, scarring alopecia, or other forms of alopecia that may affect trichoscopic assessment. 3. Patients with missing or inadequate-quality trichoscopic images at T0 or T12, preventing reliable assessment of MFU% or QTES. 4. Patients with insufficient medical records to confirm the treatment received, treatment initiation date, or assessment time points. 5. Patients who cannot be classified into any of the five treatment groups defined in this study. 6. Patients who received additional major MAGA treatments during the observation period, making it difficult to assess the association between changes in MFU% and the treatment strategy. Target Size - 125

Recruitment Status: Recruitment status - Enrolling by invitation Date of protocol fixation - 2021 Year 01 Month 01 Day Date of IRB - 2026 Year 11 Month 12 Day Anticipated trial start date - 2021 Year 01 Month 01 Day Last follow-up date - 2028 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072915

Disclaimer: Curated by HT Syndication.